Use of LSD1 inhibitor in promoting differentiation of ipsc to HSC and stemness maintenance of hsc
By using LSD1 inhibitors such as OG-L002 and SP2509 during iPSC differentiation, EPCR expression was improved, and CD34, CD90, EPCR, ITGA3 expression was maintained during HSC dry maintenance, hematopoietic stem cells were solved during in vitro expansion. Dry maintenance problems have improved the functional and transplant potential of HSCs.
Patent Information
- Application Number
- PCT/CN2024/094661
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-22
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-28
AI Technical Summary
In the prior art, hematopoietic stem cells are difficult to maintain their stemness when they amplify in vitro, resulting in the loss of the ability of self-renewal and differentiation. The HSCs obtained by iPSC differentiation have strong heterogeneity, and the proportion of hematopoietic stem cells in the long term is low, making it difficult to meet the clinical Application requirements.
Using LSD1 inhibitors, such as OG-L002 and SP2509, the expression of key proteins EPCR is improved by adding these inhibitors during the differentiation of iPSCs to HSCs, and CD34, CD90, EPCR, ITGA3, etc. are maintained during the in vitro dry maintenance of HSCs. Expression of dry markers, prolonging the number of days of dry maintenance.
It significantly promoted the differentiation of iPSC to HSC, improved the acquisition of CD34+EPCR+CD90+ITGA3+ long-term regenerated hematopoietic stem cells, and maintained its functional and transplant potential during HSC dry maintenance, extending the number of days of dry maintenance to more than one week.
Smart Images

Figure CN2024094661_28112024_PF_FP_ABST
Abstract
Description
Application of LSD1 inhibitors in promoting iPSC differentiation into HSC and maintaining HSC stemness
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to the following application documents: invention patent application with application number 2023105744356, filed on May 22, 2023, and entitled “Application of LSD1 inhibitors in promoting differentiation of iPSC to HSC and maintaining HSC stemness”, the contents of which are incorporated by reference in their entirety. Technical Field
[0003] The present invention belongs to the field of biomedicine technology. Specifically, the present invention relates to the use of LSD1 inhibitors in promoting the differentiation of iPSCs into HSCs and maintaining the stemness of HSCs. Background Art
[0004] Hematopoietic Stem Cells (HSCs) are a type of adult stem cell with the ability to self-renew and multipotently differentiate. They can produce daughter hematopoietic stem cells through cell division and can also differentiate into all functional mature blood cells. Therefore, HSCs maintain the normal hematopoietic process in the body and also play an important role in the treatment of many hematopoietic system-related diseases. Hematopoietic stem cell transplantation and gene therapy based on hematopoietic stem cell gene editing have become the most effective clinical treatment options for leukemia, lymphoma and other related blood diseases. Rebuilding the entire hematopoietic system through hematopoietic stem cell transplantation and maintaining hematopoietic capacity for a long time provide new vitality and hope for patients undergoing hematopoietic stem cell transplantation reconstruction. At present, in vitro expansion of HSCs is an important research field because it can provide more sources for hematopoietic stem cell transplantation and is expected to be used to treat a variety of blood diseases.
[0005] However, the content of hematopoietic stem cells in adult bone marrow is only approximately 0.01%. Hematopoietic stem cells used in cell transplantation are primarily isolated from the body. However, their extremely low abundance and inability to expand and culture long-term in vitro severely restrict the clinical research and application of hematopoietic stem cells. Therefore, developing new methods to obtain HSCs of sufficient quantity and purity has become a research hotspot and challenge. Furthermore, hematopoietic stem cells have difficulty maintaining their stemness during in vitro expansion, meaning they tend to lose their self-renewal and differentiation abilities, resulting in the inability of the expanded cells to be effectively transplanted and used therapeutically. This may be due to a lack of proper signaling and intercellular interactions during in vitro culture, or to alterations in the epigenetic state of HSCs, leading to changes in their gene expression patterns. The most typical hallmark of this is decreased expression of stemness markers such as CD34, CD90, EPCR, and ITGA3.
[0006] In recent years, the differentiation of induced pluripotent stem cells (iPSCs) into HSCs has become a new source. Obtaining a large number of HSCs through iPSC differentiation can effectively solve the above bottlenecks and provide a new approach for hematopoietic stem cell transplantation and reconstruction. However, compared with HSCs derived from the body, HSCs differentiated from iPSCs have disadvantages such as strong heterogeneity. In particular, the low proportion of long-term hematopoietic stem cells (LT-HSCs) is one of the difficulties that urgently needs to be optimized and resolved. Therefore, it is necessary to further optimize the process and conditions for the differentiation of iPSCs into HSCs to improve the quality and quantity of HSCs differentiated from iPSCs, obtain HSCs with stronger stemness and functionality, and lay a more solid foundation for clinical applications. In addition, how to maintain the stemness of HSCs still requires further research to provide a reliable source for future clinical applications. At present, there are no related studies or reports on the use of LSD1 inhibitors to promote the differentiation of iPSCs into HSCs and maintain the stemness of HSCs.
[0007] Summary of the Invention
[0008] In view of the above technical problems existing in the prior art, the purpose of the present invention is to provide the use of LSD1 inhibitors in promoting the differentiation of iPSCs into HSCs and maintaining the stemness of HSCs.
[0009] In order to achieve the above object, the present invention adopts the following technical solutions:
[0010] A first aspect of the present invention provides use of a LSD1 inhibitor in promoting the differentiation of iPSCs into HSCs.
[0011] Furthermore, the LSD1 inhibitors include: OG-L002, SP2509, GSK-LSD1 2HCl, Pulrodemstat (CC-90011) besylate, Iadademstat (ORY-1001) 2HCl, Seclidemstat (SP-2577), GSK2879552 2HCl, T-3775440HCl, shRNA that reduces LSD1 expression, and / or siRNA that reduces LSD1 expression.
[0012] Furthermore, the LSD1 inhibitor is OG-L002 and / or SP2509.
[0013] Furthermore, the concentration of OG-L002 is 0.1-20 μM, and the concentration of SP2509 is 0.1-5 μM.
[0014] Furthermore, the HSC is a long-term hematopoietic stem cell, and the long-term hematopoietic stem cell is a CD34+EPCR+CD90+ITGA3+ long-term hematopoietic stem cell.
[0015] In some embodiments, the present invention increases the expression of the key protein EPCR and promotes the acquisition of CD34+EPCR+CD90+ITGA3+ long-term regenerative hematopoietic stem cells by adding LSD1 inhibitors on Day 6 or Day 9 of the iPSC to HSC differentiation process.
[0016] In some embodiments, LSD1 refers to histone demethylase 1, the first discovered histone-specific demethylase. LSD1 catalyzes flavin adenine dinucleotide (FAD) and belongs to the monoamine oxidase family. Structurally, LSD1 comprises an N-terminal SWIRM domain, a C-terminal AOL (amino oxidase) domain, and a centrally located Tower domain. Existing studies have confirmed that LSD1 is closely associated with the occurrence and progression of tumors.
[0017] In some embodiments, the LSD1 inhibitor is OG-L002 and / or SP2509, both purchased from Selleck with catalog numbers S7237 and S7680, respectively. OG-L002 at a concentration of 0.1-20 μM and SP2509 at a concentration of 0.1-5 μM significantly promoted iPSC differentiation into HSCs, increasing EPCR expression and promoting the generation of CD34+EPCR+CD90+ITGA3+ long-term regenerative hematopoietic stem cells.
[0018] In some embodiments, the LSD1 inhibitor is not limited to the specific agents listed in the present invention. Any agent that can inhibit LSD1 and any agent that can achieve LSD1 knockdown and expression intervention through gene editing technology are within the scope of protection of the present invention.
[0019] The second aspect of the present invention provides use of an LSD1 inhibitor in maintaining HSC stemness.
[0020] Furthermore, the LSD1 inhibitors include: OG-L002, SP2509, GSK-LSD1 2HCl, Pulrodemstat (CC-90011) besylate, Iadademstat (ORY-1001) 2HCl, Seclidemstat (SP-2577), GSK2879552 2HCl, T-3775440HCl, shRNA that reduces LSD1 expression, and / or siRNA that reduces LSD1 expression.
[0021] Furthermore, the LSD1 inhibitor is OG-L002 and / or SP2509.
[0022] Furthermore, the concentration of OG-L002 is 2-10 μM, and the concentration of SP2509 is 0.5-5 μM.
[0023] Furthermore, the HSC includes iPSC-derived HSC or umbilical cord blood-derived HSC.
[0024] Furthermore, the LSD1 inhibitor can maintain the expression of HSC stemness-related genes CD34, CD90, EPCR, and ITGA3, and increase the expression level of EPCR.
[0025] In some embodiments, the present invention achieves the maintenance of the stemness of iPSC-derived and umbilical cord blood-derived HSCs by adding LSD1 to the in vitro stemness maintenance and expansion culture medium of iPSC-derived and umbilical cord blood-derived HSCs, maintaining their stemness for more than one week (the expression of stemness-related genes CD34, CD90, EPCR, and ITGA3 can reach more than one week), and increasing the expression levels of key genes such as EPCR, laying the foundation for ultimately achieving the functional continuation of hematopoietic stem cells and better transplantation effects.
[0026] In some embodiments, the HSC is not limited to iPSC-derived HSC or umbilical cord blood-derived HSC, and HSC from any source is within the scope of protection of the present invention.
[0027] In some embodiments, the maintenance of stemness is mainly reflected in high proliferation, low differentiation, self-renewal, migration ability and the expression of stemness-related genes (such as CD34, CD90, EPCR and ITGA3), among which the most typical markers are mainly reflected in the expression of stemness-related genes (such as CD34, CD90, EPCR and ITGA3).
[0028] A third aspect of the present invention provides a method for promoting the differentiation of iPSCs into HSCs.
[0029] Furthermore, the method comprises the following step: using the LSD1 inhibitor described in the first aspect of the present invention to promote the differentiation of iPSCs into HSCs.
[0030] Furthermore, the method comprises the following steps:
[0031] (1) Day 1, iPSC monolayer adherent cell formation;
[0032] (2) Day 0, mesendoderm induction, iPSCs obtained in step (1) were cultured using mesendoderm induction medium;
[0033] (3) Day 1-2, hematopoietic mesoderm specification, culturing the cells obtained in step (2) using hematopoietic mesoderm specification medium;
[0034] (4) Day 3-Day 12, hemogenic endothelial specialization and endothelial-hematopoietic cell transformation. The cells obtained in step (3) are cultured in hemogenic endothelial specialization and endothelial-hematopoietic cell transformation medium, and LSD1 inhibitor is added. On Day 12, HSC cells are collected.
[0035] Furthermore, the mesoderm induction medium in step (2) comprises: STEMdiff TM APEL TM 2 Medium, Penicillin-Streptomycin, CHIR99021.
[0036] Furthermore, the contents of the components in the mesoderm induction medium are: 1% Penicillin-Streptomycin, 9 μM CHIR99021.
[0037] Furthermore, the hematopoietic mesoderm specialized culture medium in step (3) comprises: STEMdiff TM APEL TM 2 Medium, Penicillin-Streptomycin, VEGF, bFGF.
[0038] Furthermore, the contents of the components in the hematopoietic mesoderm specialized culture medium are: 1% Penicillin-Streptomycin, 20 ng / mL VEGF, and 20 ng / mL bFGF.
[0039] Furthermore, the hemogenic endothelial specialization and endothelial-hematopoietic cell conversion culture medium in step (4) comprises: STEMdiff TM APEL TM 2 Medium, Penicillin-Streptomycin, VEGF, bFGF, SCF, IL-3, TPO, Flt-3L, BMP4.
[0040] Furthermore, the contents of the components in the hemogenic endothelial specialization and endothelial-hematopoietic cell conversion medium are: 1% Penicillin-Streptomycin, 20 ng / mL VEGF, 20 ng / mL bFGF, 20 ng / mL SCF, 10 ng / mL IL-3, 30 ng / mL TPO, 10 ng / mL Flt-3L, and 10 ng / mL BMP4.
[0041] Furthermore, the hemogenic endothelial specialization and endothelial-hematopoietic cell conversion culture medium further contains Y-27632.
[0042] Furthermore, the concentration of Y-27632 is 10 μM.
[0043] Furthermore, the LSD1 inhibitor in step (4) is added on Day 6 or Day 9.
[0044] Furthermore, the LSD1 inhibitor in step (4) is added daily from Day 6 to Day 12 or from Day 9 to Day 12.
[0045] Furthermore, the LSD1 inhibitor in step (4) includes: OG-L002, SP2509, GSK-LSD1 2HCl, Pulrodemstat (CC-90011) besylate, Iadademstat (ORY-1001) 2HCl, Seclidemstat (SP-2577), GSK2879552 2HCl, T-3775440HCl, shRNA that reduces LSD1 expression, and / or siRNA that reduces LSD1 expression.
[0046] Furthermore, the LSD1 inhibitor is OG-L002 and / or SP2509.
[0047] Furthermore, the concentration of OG-L002 is 0.1-20 μM, and the concentration of SP2509 is 0.1-5 μM.
[0048] Furthermore, the HSC is a long-term hematopoietic stem cell, and the long-term hematopoietic stem cell is a CD34+EPCR+CD90+ITGA3+ long-term hematopoietic stem cell.
[0049] The present invention also provides HSCs prepared by the method described in the third aspect of the present invention, and pharmaceutical compositions or pharmaceutical preparations comprising the HSCs.
[0050] In some embodiments, the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier and / or excipient, including but not limited to a diluent, a binder, a surfactant, a humectant, an adsorbent, a lubricant, a filler, and a disintegrant.
[0051] In some embodiments, the dosage form of the pharmaceutical preparation includes a non-gastrointestinal dosage form and a gastrointestinal dosage form. The non-gastrointestinal dosage form includes an injection dosage form, a respiratory tract dosage form, a cavity dosage form, a mucosal dosage form, and a skin dosage form. The gastrointestinal dosage form includes a tablet, a granule, a capsule, a solution, a powder, a sustained-release agent, an effervescent agent, an emulsion, a suspension, a syrup, a drop, and a chewable tablet.
[0052] In some embodiments, the injection dosage forms include but are not limited to: subcutaneous injection, intravenous injection, intramuscular injection, intradermal injection and intracavitary injection and other injections; the respiratory tract administration dosage forms include but are not limited to: sprays, aerosols, powder aerosols, etc.; the cavity administration dosage forms include but are not limited to: suppositories, aerosols, effervescent tablets, drops, pills, etc., for use in the rectum, vagina, urethra, nasal cavity, ear canal, etc.; the mucosal administration dosage forms include but are not limited to: eye drops, nasal drops, eye ointments, gargles, sublingual tablets, adhesive tablets, patches, etc.; the skin administration dosage forms include but are not limited to: external use solutions, lotions, liniments, ointments, plasters, pastes, patches, etc.
[0053] In some embodiments, the appropriate dosage of the HSC, pharmaceutical composition or pharmaceutical preparation of the present invention can be prescribed in a variety of ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, morbidity, diet, administration time, administration route, excretion rate and reaction sensitivity. A skilled physician can usually easily determine the prescription and the desired therapeutically effective dosage. As long as it can produce the expected therapeutic effect, such dosage is within the scope of protection of the present invention.
[0054] The present invention also provides the use of HSCs prepared by the method described in the third aspect of the present invention in treating blood system diseases.
[0055] The present invention also provides a method for treating blood system diseases, comprising the following steps: administering to a subject in need thereof a therapeutically effective amount of HSCs prepared by the method described in the third aspect of the present invention.
[0056] In some embodiments, the blood system disease includes but is not limited to: acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, aplastic anemia, thalassemia, lupus erythematosus, and hemolytic anemia.
[0057] In some embodiments, the effective amount refers to an amount of the target substance (in the present invention, particularly HSC prepared using the method described in the third aspect of the present invention) that effectively produces the desired preventive, allergic, or therapeutic effect. The amount of the target substance, pharmaceutical composition, or pharmaceutical preparation of the present invention required to achieve an effective amount will vary depending on factors such as the target substance, the symptoms and their severity, and the age of the mammal being treated. However, the specific amount can be routinely determined by a person of ordinary skill in the art based on their knowledge in the field and the disclosure herein. Doses that can produce the aforementioned effects are within the scope of the present invention.
[0058] In some embodiments, the subject includes mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the class Mammalia: humans, non-human primates such as chimpanzees and other apes and monkeys; farm animals such as cattle, horses, sheep, goats, and pigs; domestic animals such as rabbits, dogs, and cats; and laboratory animals, including rodents such as rats, mice, and guinea pigs. Examples of non-mammals include, but are not limited to, birds, fish, and the like. In other embodiments, the subject is preferably human.
[0059] In some embodiments, the administration of the HSC, pharmaceutical composition or pharmaceutical formulation can be carried out in any form, including but not limited to: subcutaneous injection, intravenous, oral, topical, parenteral, intramuscular, transdermal (which may include a penetration enhancer), oral and / or suppository administration, as well as other routes of administration. In one embodiment of the present invention, the HSC, pharmaceutical composition or pharmaceutical formulation as described above is provided in an injectable dosage form as is known in the art. The most effective dosage form will depend on the bioavailability or pharmacokinetics of the particular agent selected and the severity of the patient's disease.
[0060] A fourth aspect of the present invention provides a method for maintaining HSC stemness.
[0061] Furthermore, the method comprises the following steps: culturing HSCs in an HSC stemness maintenance and expansion medium, and adding an LSD1 inhibitor.
[0062] Furthermore, the HSC stemness maintenance and expansion medium comprises: StemSpan TM SFEM Medium, Flt3L, SCF, TPO, IL-3, UM171, VPA, LAA, Trolox, NAC, SR1, PVA, ITS-X.
[0063] Furthermore, the contents of the components in the HSC stemness maintenance and expansion medium are: 50 ng / mL Flt3L, 50 ng / mL SCF, 50 ng / mL TPO, 10 ng / mL IL-3, 35 nM UM171, 1 μM VPA, 50 μg / mL LAA, 50 μM Trolox, 50 μM NAC, 0.5 μM SR1, 1% PVA, and 1% ITS-X.
[0064] Furthermore, the LSD1 inhibitors include: OG-L002, SP2509, GSK-LSD1 2HCl, Pulrodemstat (CC-90011) besylate, Iadademstat (ORY-1001) 2HCl, Seclidemstat (SP-2577), GSK2879552 2HCl, T-3775440HCl, shRNA that reduces LSD1 expression, and / or siRNA that reduces LSD1 expression.
[0065] Furthermore, the LSD1 inhibitor is OG-L002 and / or SP2509.
[0066] Furthermore, the concentration of OG-L002 is 2-10 μM, and the concentration of SP2509 is 0.5-5 μM.
[0067] Furthermore, the HSC includes iPSC-derived HSC or umbilical cord blood-derived HSC.
[0068] Furthermore, the LSD1 inhibitor can maintain the expression of HSC stemness-related genes CD34, CD90, EPCR, and ITGA3, and increase the expression level of EPCR.
[0069] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. In order to facilitate understanding of the present invention, the following terms involved in the present invention are explained here:
[0070] As used herein, the term "or" refers to a single element of a listed alternative element unless the context clearly dictates otherwise.
[0071] As used herein, the term "and / or" means any one, any two, any three, any more or all of the listed optional elements.
[0072] As used herein, the term "hematopoietic stem cell (HSC)" refers to an immature blood cell with the ability to self-renew and differentiate into mature blood cells containing cells of different lineages, including but not limited to granulocytes (e.g., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), coagulocytes (e.g., promegakaryocytes, platelet-producing megakaryocytes, platelets), monocytes (e.g., monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g., NK cells, B cells, and T cells). Additionally, HSC also refers to long-term regenerative hematopoietic stem cells (LT-HSC) and short-term regenerative hematopoietic stem cell HSC (ST-HSC). Based on functional potential and cell surface marker expression, LT-HSCs and ST-HSCs are differentiated, with LT-HSCs having a more robust self-renewal potential (i.e., they survive throughout adulthood and can be serially transplanted into serial recipients), while ST-HSCs have a limited self-renewal capacity (i.e., they survive only for a limited period of time and do not possess serial transplantation potential). In a specific embodiment of the present invention regarding "the use of an LSD1 inhibitor in promoting the differentiation of iPSCs into HSCs," the HSC is preferably a LT-HSC.
[0073] As used herein, the term "induced pluripotent stem cells (iPSC)" refers to stem cells with totipotency or pluripotency obtained from certain adult cells by artificially inducing the expression of certain genes. In some methods known in the art, iPSC can be obtained by transfecting certain stem cell-related genes into non-pluripotent cells such as adult fibroblasts. Transfection can be achieved by viral transduction using viruses such as retroviruses or lentiviruses. In some methods, the transfected genes may include transcription factors Oct4, Sox2, Klf4, and c-Myc, although it is possible to improve the induction efficiency by transfecting other genes at the same time. In other methods, Oct4, Sox2, Nanog, and Lin28 genes can be used to transform somatic cells using a lentiviral system. Genes induced to express in iPSCs include, but are not limited to, Oct-3 / 4; certain members of the Sox gene family (e.g., Sox1, Sox2, Sox3, and Sox15); certain members of the Klf family (e.g., Klf1, Klf2, Klf4, and Klf5), certain members of the Myc family (e.g., C-myc, L-myc, and N-myc), Nanog, Lin28, Tert, Fbx15, ERas, ECAT15-1, ECAT15-2, Tcl1, β-Catenin, ECAT1, Esg1, Dnmt3L, ECAT8, Gdf3, Fth117, Sal14, Rex1, UTF1, Stella, Stat3, Grb2, Prdm14, Nr5a1, Nr5a2, or E-cadherin, or any combination thereof. Currently, various reagents for preparing iPSCs, such as reprogramming vectors, expression cassettes, culture media, and even commercial iPSCs, are commercially available. hiPSCs refer to iPSCs derived from human somatic cells. In specific embodiments of the present invention, the hiPSCs used in the examples were prepared according to the method described in Chinese Patent Publication No. CN113462638A, which is incorporated herein by reference in its entirety.
[0074] As used herein, the term "mesoderm induction" refers to the process of culturing iPSCs in a mesoderm induction medium to produce mesoderm cells with mesoderm cell markers. Methods for generating mesoderm cells from iPSCs are known in the art, for example, commercial mesoderm induction mediums such as STEMdiff are available. TM Mesoderm induction medium; in addition, Chinese Patent Publication CN111321110A describes a method for inducing the generation of mesoderm cells from iPSCs, and Chinese Patent Publication CN106867961A describes a culture medium and method for inducing the generation of mesoderm cells from iPSCs.
[0075] As used herein, the term "hematopoietic mesoderm specification" refers to the process of inducing the differentiation of mesodermal cells into "hematopoietic mesoderm cells." "Hematopoietic mesoderm cells" can be considered as precursor cells of hematopoietic endothelial cells.
[0076] As used herein, the term "Hematopoietic & Endothelial Specification" refers to the process of inducing the differentiation of hematopoietic mesoderm cells into "hemogenic endothelium cells".
[0077] As used herein, the term "endothelial-to-hematopoietic transition" refers to the process by which hematopoietic endothelial cells transform into hematopoietic stem cells or hematopoietic progenitor cells. This process can ultimately produce hematopoietic stem cells with therapeutic applications, including long-term regenerative hematopoietic stem cells (LT-HSC). Hematopoietic stem cells or hematopoietic progenitor cells can be isolated or identified by cell markers such as CD34, CD45, CD90, CD45RA, EPCR or ITGA3. In some embodiments, the present invention identifies long-term regenerative hematopoietic stem cells by the markers CD34, CD90, EPCR and ITGA3. In a specific embodiment, the present invention characterizes long-term regenerative hematopoietic stem cells by CD34+EPCR+CD90+ITGA3+. Among them, EPCR can participate in the regulation of HSC and its microenvironment through pathways such as the protease-activated receptor (PAR) 1 signaling pathway, mediate the retention of HSC in the bone marrow and the reconstitution of hematopoietic function, and plays an important role in the function realization of HSC. It is an extremely critical protein. How to maintain and upregulate the expression of EPCR during HSC expansion in vitro is also of great practical significance.
[0078] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0079] The present invention creatively discovered for the first time that adding an LSD1 inhibitor during the differentiation of iPSCs into HSCs not only increases the expression of the key protein EPCR, but also promotes the acquisition of CD34+EPCR+CD90+ITGA3+ long-term regenerative hematopoietic stem cells. Furthermore, the present invention discovered for the first time that an LSD1 inhibitor plays an important regulatory role in maintaining the stemness of iPSC-derived and cord blood-derived HSCs, maintaining stemness for more than a week and increasing the expression of related stemness markers such as EPCR, thus improving HSC functionality and transplantation potential, laying the foundation for achieving continued HSC function and better transplantation outcomes. BRIEF DESCRIPTION OF THE DRAWINGS
[0080] Figure 1 is a flowchart of the experimental process of iPSC differentiation into HSC;
[0081] Figure 2 shows the cell morphology on Day 3 of iPSC differentiation into HSC;
[0082] Figure 3 shows the cell morphology on Day 6 of iPSC differentiation into HSC;
[0083] Figure 4 shows the cell morphology on Day 12 of iPSC differentiation into HSC;
[0084] FIG5 is a flow cytometry result of Day 3 differentiation of iPSC into HSC;
[0085] Figure 6 shows the flow cytometry results of iPSC differentiation into HSC on Day 6;
[0086] Figure 7 shows the gating strategy for four positive cells. First, CD34+ / EPCR+ double positive cells were circled based on the expression of CD34 and EPCR. The positive ratios of CD90 and ITGA3 were calculated among the double positive cells, and finally the proportion of four positive cells in the upper right quadrant was obtained.
[0087] FIG8 is a flow cytometry result of iPSC differentiation into HSC on Day 12;
[0088] Figure 9 is a graph showing the HSC Day 0 stemness marker flow chart;
[0089] FIG10 is a graph showing the effects of different drug treatments on HSC cell morphology (Day 3) on Day 0;
[0090] FIG11 is a flow cytometry result of Day 3 HSC stemness markers (CD34 / CD90);
[0091] FIG12 is a flow cytometry result of HSC stemness markers (CD34 / EPCR / CD90 / ITGA3) on Day 3;
[0092] FIG13 is a graph showing the effects of different drug treatments on Day 0 on HSC cell proliferation and cell morphology on Day 5;
[0093] FIG14 is a flow cytometry result of HSC stemness markers (CD34 / CD90) on Day 6;
[0094] FIG15 is a flow cytometry result of HSC stemness markers (CD34 / EPCR / CD90 / ITGA3) on Day 6;
[0095] FIG16 shows the effects of different drug treatments on Day 0 on cell proliferation and cell morphology on Day 9;
[0096] FIG17 is a flow cytometry result of Day 9 HSC stemness markers (CD34 / CD90);
[0097] FIG18 is a flow cytometry result of HSC stemness markers (CD34 / EPCR / CD90 / ITGA3) on Day 9;
[0098] FIG19 is a statistical diagram of the flow cytometry results of HSC stemness maintenance;
[0099] FIG20 is a graph showing changes in HSC stemness markers from Day 0 to Day 3 in the control group;
[0100] FIG21 is a graph showing the effects of different treatment time windows on the expression of HSC stemness markers (CD34 / EPCR) (Day 3 detection);
[0101] FIG22 is a graph showing the effect of different concentrations of OG on the expression of HSC stemness markers (CD34 / EPCR) (Day 3 detection);
[0102] FIG23 is a graph showing the effect of different concentrations of SP on the expression of HSC stemness markers (CD34 / EPCR) (Day 3 detection);
[0103] FIG24 is a graph showing the effect of different OG treatment time windows on the expression of HSC stemness markers (CD34 / EPCR) (Day 6 detection);
[0104] FIG25 is a graph showing the effect of OG+SP combined treatment at different treatment time windows on the expression of HSC stemness markers (CD34 / EPCR) (Day 6 detection);
[0105] FIG26 is a graph showing the effect of different concentrations of OG on the expression of HSC stemness markers (CD34 / EPCR) (Day 6 detection);
[0106] FIG27 is a graph showing the effect of different concentrations of SP on the expression of HSC stemness markers (CD34 / EPCR) (Day 6 detection);
[0107] FIG28 is a graph showing the results of flow cytometry detection of stemness marker expression levels in cord blood-derived CD34+ cells;
[0108] FIG29 shows the cell morphology of cord blood-derived HSCs on Day 3 and Day 4 of in vitro stemness maintenance and expansion;
[0109] FIG30 is a graph showing the expression levels of stemness markers (CD34 / CD90) on Day 3 of in vitro maintenance and expansion of cord blood-derived HSCs;
[0110] FIG31 is a graph showing the expression levels of stemness markers (CD34 / EPCR) on Day 3 of in vitro maintenance and expansion of cord blood-derived HSCs;
[0111] FIG32 is a graph showing the expression of CD90 and ITGA3 in Day 3 CD34 / EPCR double positive cells for maintenance of stemness and expansion of cord blood-derived HSCs in vitro;
[0112] FIG33 shows the cell morphology of cord blood-derived HSCs on Day 6 and Day 7 of in vitro stemness maintenance and expansion;
[0113] FIG34 is a graph showing the expression levels of stemness markers (CD34 / CD90) on Day 6 of in vitro maintenance and expansion of cord blood-derived HSCs;
[0114] FIG35 is a graph showing the expression levels of stemness markers (CD34 / EPCR) on Day 6 of in vitro maintenance and expansion of cord blood-derived HSCs;
[0115] FIG36 shows the cell morphology of cord blood-derived HSCs on Day 8 and Day 9 of in vitro stemness maintenance and expansion;
[0116] FIG37 is a graph showing the expression levels of stemness markers (CD34 / CD90) on Day 9 of in vitro maintenance and expansion of cord blood-derived HSCs;
[0117] FIG38 shows the expression levels of stemness markers (CD34 / EPCR) on Day 9 of in vitro maintenance and expansion of cord blood-derived HSCs. DETAILED DESCRIPTION
[0118] The present invention will be further described below in conjunction with specific examples, which are intended only to explain the present invention and are not to be construed as limiting the present invention. Those skilled in the art will appreciate that various changes, modifications, substitutions, and variations may be made to these examples without departing from the principles and aims of the present invention, and that the scope of the present invention is defined by the claims and their equivalents. The experimental methods in the following examples, for which specific conditions are not specified, are generally tested under conventional conditions or under conditions recommended by the manufacturer.
[0119] Example 1 iPSC to HSC differentiation process
[0120] 1. Experimental Materials
[0121] The experimental materials used in the examples are shown in Table 1 below.
[0122] Table 1 Experimental materials
[0123] 2. Experimental methods
[0124] The experimental process of iPSC differentiation into HSC is shown in Figure 1. The specific experimental methods are as follows:
[0125] (1) Formation of adherent cell monolayer (Day-1)
[0126] ① Prepare TrypLE working solution: pipette 5 mL of DPBS into a new 15 mL centrifuge tube, then add 5 mL of TrypLE stock solution and mix thoroughly to obtain the TrypLE working solution.
[0127] ② According to the volume of culture medium required for subculturing, prepare E8 complete culture medium containing 1% PS (Penicillin-Streptomycin) and 10 μM Y-27632 (ROCKi), and add 1 μL Y-27632 (10 mM) stock solution per mL of culture medium.
[0128] ③ Remove the well plate / culture flask to be passaged (containing hiPSCs, the hiPSCs are the induced pluripotent stem cells hiPS-001-5 prepared by the inventors, for preparation methods, see CN113462638A) from the incubator, aspirate the supernatant, and wash twice with DPBS (each time using at least the amount of DPBS used in the original culture medium), each time for 1 min (during washing, leave the DPBS in the well / flask for 30-45 seconds before aspirating it).
[0129] ④ After adding TrypLE working solution (add about 1 mL of TrypLE working solution to a six-well plate and about 2 mL of TrypLE working solution to a T25 flask), place the plate in an incubator and incubate for 2-5 minutes. During this period, observe under a microscope and see if the cells shrink, become round, and disperse.
[0130] ⑤ Gently tap the culture flask / plate to detach the cells from the bottom of the plate, then gently pipette and vortex several times. Finally, add DMEM / F12 to terminate the digestion. Pipette an appropriate amount of cell suspension and count.
[0131] ⑥ After balancing, centrifuge at 200g for 5 minutes. After the centrifugation is completed, aspirate and discard the supernatant. Gently shake the bottom of the centrifuge tube. According to different cell densities, add E8 complete medium containing 10μM Y-27632 to resuspend. After the cells are fully mixed, drop the cell suspension into the wells of the culture plate. The cell density is 8000 cells / cm 2 , placed in a 37°C, 5% CO2 incubator for static culture.
[0132] ⑦ After culturing for 24 hours, wash twice with DPBS and then proceed with subsequent differentiation induction.
[0133] (2) hiPSCs induce HSC differentiation—Mesoderm Induction (Day 0)
[0134] ① Prepare an appropriate amount of mesoderm induction medium: STEMdiff TM APEL TM 2. Medium + 1% Penicillin-Streptomycin + 9μM CHIR99021, preheated in a 37℃ water bath.
[0135] ② Aspirate and discard the original culture medium and add appropriate amount of DPBS to wash the cells.
[0136] ③Add mesoderm induction medium (STEMdiff TM APEL TM 2 Medium + 1% Penicillin-Streptomycin + 9 μM CHIR99021), and then placed in a 37°C, 5% CO2 incubator for 24 hours. This is recorded as Day 0.
[0137] (3) hiPSCs induce HSC differentiation—Hematopoietic Mesoderm Specification (Day 1-2)
[0138] ① Prepare an appropriate amount of hematopoietic mesoderm specialized culture medium: STEMdiff TM APEL TM 2. Add Medium + 1% Penicillin-Streptomycin + 20 ng / mL VEGF + 20 ng / mL bFGF, preheat in a 37°C water bath.
[0139] ② Aspirate and discard the original culture medium and add appropriate amount of DPBS to wash the cells.
[0140] ③Add hematopoietic mesoderm specialized medium (STEMdiff TM APEL TM 2 Medium + 1% Penicillin-Streptomycin + 20 ng / mL VEGF + 20 ng / mL bFGF), and then placed in a 37°C, 5% CO2 incubator for 48 hours. This is recorded as Day 1.
[0141] (4) hiPSCs induce HSC differentiation—Hematopoietic & Endothelial Specification and Endothelial-to-Hematopoietic Transition (Day 3-Day 12)
[0142] ① Prepare an appropriate amount of hemogenic endothelial specialization and endothelial-hematopoietic cell conversion medium: STEMdiff TM APEL TM 2. Medium + 1% Penicillin-Streptomycin + 20 ng / mL VEGF + 20 ng / mL bFGF + 20 ng / mL SCF + 10 ng / mL IL-3 + 30 ng / mL TPO + 10 ng / mL Flt-3L + 10 ng / mL BMP4. Preheat the medium in a 37°C water bath.
[0143] ② After 48 hours of hematopoietic mesoderm specialization, the original culture medium was discarded; an appropriate amount of DPBS was added to wash the cells, and the cells were digested to single cells with TrypLE working solution to terminate the cell digestion. After centrifugation at 200g for 5 minutes, the cells were resuspended in hemogenic endothelial specialization and endothelial-hematopoietic cell conversion medium, and 10μM Y-27632 was added. The cells were centrifuged at 20,000 cells / cm 2 The cells were inoculated and then placed in a 37°C, 5% CO2 incubator for static culture (the hypoxia-induced treatment group was in a 5% CO2, 5% O2 incubator). This was recorded as Day 3.
[0144] ③ Thereafter, fresh hemogenic endothelial specialized and endothelial-hematopoietic cell transition medium (STEMdiff TM APEL TM 2 Medium+1% Penicillin-Streptomycin+20ng / mL VEGF+20ng / mL bFGF+20ng / mL SCF+10ng / mL IL-3+30ng / mL TPO+10ng / mL Flt-L+10ng / mL BMP4).
[0145] ④ On Day 6 or Day 9, the small molecule inhibitor of LSD1, 10 μM OG-L002 (OG) or 2 μM SP2509 (SP), was added.
[0146] The experimental groups were as follows: control group (no LSD1 inhibitor was added), OG D6-12 group (OG-L002 was added every day from Day 6 to Day 12, and continued for 7 days), SP D6-12 group (SP2509 was added every day from Day 6 to Day 12, and continued for 7 days), OG D9-12 group (OG-L002 was added every day from Day 9 to Day 12, and continued for 4 days), and SP D9-12 group (SP2509 was added every day from Day 9 to Day 12, and continued for 4 days).
[0147] ⑤ Until Day 12, collect the resulting suspended HSC cells.
[0148] 3. Experimental results
[0149] Figure 2 shows the cell morphology on Day 3 of iPSC differentiation into HSC. Under ordinary light microscopy, the morphology of human pluripotent stem cells (hiPS-001-5) induced to differentiate into hematopoietic mesoderm cells is shown. After induction into the hematopoietic mesoderm, the cells proliferate rapidly and exhibit a mesenchymal-like morphology. The cells are polygonal and relatively loosely arranged.
[0150] Figure 3 shows the cell morphology on Day 6 of iPSC differentiation into HSC. Under ordinary light microscopy, the morphology of human pluripotent stem cells (hiPS-001-5) induced to differentiate into hemogenic endothelial cells is shown. The cells proliferate rapidly, generating a large number of hemogenic endothelial cells. The cells are densely arranged, short spindle-shaped, and have obvious nucleoli.
[0151] The cell morphology on Day 12 of iPSC differentiation into HSC is shown in Figure 4. Under ordinary optical microscope observation, human pluripotent stem cells (hiPS-001-5) were induced to differentiate into hematopoietic stem cells, forming a large number of non-adherent, round hematopoietic stem and progenitor cells.
[0152] Example 2 Flow cytometry detection of marker gene (CD34, EPCR, CD90, ITGA3) expression of long-term regenerative hematopoietic stem cells (LT-HSC)
[0153] 1. Experimental Materials
[0154] The experimental materials used in the examples are shown in Table 2 below.
[0155] Table 2 Experimental materials
[0156] 2. Experimental methods
[0157] Flow cytometry (FACS) was used to detect cell surface markers. The specific experimental method is as follows:
[0158] (1) Reagents and antibodies required for FACS detection
[0159] ① Washing reagent: Buffer A (PBS + 4% FBS)
[0160] ② Directly labeled primary antibodies: FITC anti-human CD34, PE anti-human EPCR, PerCP / Cyanine5.5 anti-human CD90, APC anti-human ITGA3
[0161] (2) Preparation of test samples
[0162] ① Identify the cells to be tested, aspirate the old culture medium, wash once with PBS, add preheated TrypLE digestion solution, and digest at 37°C for 3 minutes. After blowing the cells apart with a pipette, transfer them to a 15mL centrifuge tube containing differentiation medium with 10% FBS. Terminate TrypLE digestion, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant.
[0163] ②Wash the cells twice with Buffer A, adding 3 mL of Buffer B each time, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant.
[0164] ③ Incubate with directly labeled primary antibody: Dilute the antibody with Buffer A and add 100 μL to each tube, resuspend the cells, and incubate at 4°C for 30 minutes. Gently flick the centrifuge tube every 10 minutes to allow the cells to fully bind to the antibody.
[0165] ④ Wash the cells three times with Buffer A, 3 mL each time, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant.
[0166] ⑤ Add 200 μL DPB to each tube to resuspend the cells, filter the cells through a 70 μm pore size filter to remove undigested cell clumps, transfer to a flow cytometry tube, and store at 4°C in the dark until detection on the flow cytometer.
[0167] (3) Streaming machine testing
[0168] ① Turn on the flow cytometer Guava easyCyte HT and the computer.
[0169] ② Set up the flow cytometer; open the flow cytometer software and set various parameters.
[0170] ③ After the machine changes to Ready status, clean the machine.
[0171] ④ First, using an isotype control sample, set the FSC and SSC voltages and gains to locate the discrete cell populations in the appropriate quadrants. Typically, the lower left corner represents cell debris, while the upper right corner represents larger cell clumps. Circle the target cell population, set the gate, and proceed to the next step of analysis.
[0172] ⑤ Select the appropriate detection channel based on the fluorophore conjugated to the antibody. Adjust the corresponding channel voltage and compensation to clearly distinguish the negative and positive cell populations, and then test the experimental samples in sequence.
[0173] After the test is completed, clean the flow cytometer and turn off the flow cytometer and computer.
[0174] 3. Experimental results
[0175] The flow cytometry results of Day 3 of iPSC differentiation into HSC are shown in FIG5 . The flow cytometry results of Day 3 showed that the proportion of KDR-positive cells reached 98.41%, confirming that hematopoietic mesoderm cells were successfully differentiated.
[0176] The flow cytometry results of Day 6 of iPSC differentiation into HSC are shown in Figure 6. The flow cytometry results on Day 6 showed that the proportion of KDR and CD34 double positive cells was 63.14%. Combined with the cell morphology in Figure 3, it was confirmed that hematopoietic endothelial cells were successfully differentiated.
[0177] The gating strategy for four-positive cells is shown in Figure 7. First, CD34+ / EPCR+ double-positive cells are circled based on the expression of CD34 and EPCR. The positive ratios of CD90 and ITGA3 are then counted among the double-positive cells to finally obtain the proportion of four-positive cells in the upper right quadrant.
[0178] The flow cytometry results of iPSC differentiation to HSC on Day 12 are shown in Figure 8. The flow cytometry results on Day 12 showed that the EPCR-positive ratio of the control group (compared with the LSD1 inhibitor group, no LSD1 inhibitor was added) was only 2.22%, and the double-positive ratio of CD34 and EPCR was only 2.04%. Adding LSD1 inhibitors on Day 6 and Day 9 can greatly increase the expression of EPCR, especially OG. Among them, adding OG on Day 6 or Day 9 increased the positive ratio of EPCR to about 75%, and the double-positive ratio of CD34 and EPCR to about 70%, which is 35 times that of the control group. Adding SP on Day 6 or Day 9 can also increase the EPCR-positive ratio by more than 2 times.
[0179] The proportion of LT-HSCs was only 0.66% in the control group, but when OG was added on Day 6 or Day 9, the proportion increased to 33.4% and 14.73%, respectively, which were 50 times and 22 times that of the control group. When SP was added on Day 6 or Day 9, the proportion of LT-HSCs increased to 4.43% and 2.06%, respectively, which were 6.7 times and 3.1 times that of the control group.
[0180] The statistical results of the ratio of four positive cells and the absolute number of cells are shown in Table 3 below. The results show that compared with the control group, all treatment groups of OG and SP can significantly increase the number of long-term regenerative hematopoietic stem cells (LT-HSC). The number of cells produced by the control group was 4488. When OG was added on Day 6 or Day 9, the number of four positive cells (LT-HSC) was 13360 and 66874, respectively, which were 3 times and 15 times that of the control group, respectively. When SP was added on Day 6 or Day 9, the number of four positive cells (LT-HSC) was 7442 and 10506, respectively, which were 1.65 times and 2.34 times that of the control group, respectively. In summary, it can be seen that the effect of introducing OG on Day 9 is the best. In addition, the present invention repeated the experiment using 5μM OG and 1μM SP, respectively (except for the different amounts of OG and SP, the other experimental conditions were exactly the same), and the experimental results obtained were similar.
[0181] The above experimental results show that adding small molecule inhibitors of LSD1 on Day 6 or Day 9 of the iPSC to HSC differentiation process, while increasing the expression of the key protein EPCR, significantly promoted the acquisition of CD34+EPCR+CD90+ITGA3+ long-term regenerative hematopoietic stem cells.
[0182] Table 3 Statistical results of the ratio of four positive cells and absolute cell number
[0183] Example 3 Verification of the Stemness Maintenance Effect of iPSC-Derived HSCs
[0184] 1. Experimental Materials
[0185] The experimental materials used in the examples are shown in Table 4 below.
[0186] Table 4 Experimental materials
[0187] 2. Cell Culture—In Vitro Expansion of HSCs and Treatment with LSD1 Inhibitors
[0188] iPSC-derived HSCs (HSCs were prepared using the method described in the inventor's prior patent CN115247151B) were seeded into 6-well plates at a rate of 50W / well for stemness maintenance using the "HSC Stemness Maintenance and Expansion Medium," i.e., StemSpan TM SFEM Medium+50ng / mL Flt3L+50ng / mL SCF+50ng / mL TPO+10ng / mL IL-3+35nM UM171+1μM VPA+50μg / mL LAA+50μM Trolox+50μM NAC+0.5μM SR1+1% PVA+1% ITS-X.
[0189] Stemness maintenance groups were treated with varying concentrations of OG-L002 and / or SP2509 for 9 days, with the medium changed every 2 days. (For suspension-cultured HSC cells, cells were transferred to a 15 mL centrifuge tube using a pipette, centrifuged at 1000 rpm for 5 minutes, the supernatant discarded, and resuspended in 3 mL of HSC Stemness Maintenance and Expansion Medium before being transferred to a 6-well plate for culture.) Compared to the stemness maintenance groups, the control group (CK group) was not supplemented with OG-L002 and / or SP2509. Flow cytometry analysis of four stemness markers was performed on Day 0, Day 3, Day 6, and Day 9.
[0190] 3. Flow cytometry - detection of four stemness markers: CD34, CD90, EPCR, and ITGA3
[0191] (1) Reagents and antibodies required for FACS detection
[0192] ① Washing reagent: Buffer A (PBS + 4% FBS)
[0193] ② Directly labeled primary antibodies: FITC anti-human CD34, PE anti-human EPCR, PerCP / Cyanine5.5 anti-human CD90, APC anti-human ITGA3
[0194] (2) Preparation of test samples
[0195] ① For suspension cultured HSC cells, transfer the cells to a 15 mL centrifuge tube using a pipette, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant.
[0196] ②Wash the cells twice with 3 mL of Buffer A each time, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant.
[0197] ③ Incubate with directly labeled primary antibody: Dilute the antibody with Buffer A and add 100 μL to each tube, resuspend the cells, and incubate at 4°C for 30 minutes. Gently flick the centrifuge tube every 10 minutes to allow the cells to fully bind to the antibody.
[0198] ④ Wash the cells three times with 3 mL of Buffer A each time, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant.
[0199] ⑤ Add 200 μL DPB to each tube to resuspend the cells, filter the cells through a 70 μm pore size filter to remove undigested cell clumps, transfer to a flow cytometry tube, and store at 4°C in the dark until detection on the flow cytometer.
[0200] (3) Streaming machine testing
[0201] ① Turn on the flow cytometer Guava easyCyte HT and the computer.
[0202] ② Set up the flow cytometer; open the flow cytometer software and set various parameters.
[0203] ③ After the machine changes to Ready status, clean the machine.
[0204] ④ First, using an isotype control sample, set the FSC and SSC voltages and gains to locate the discrete cell populations in the appropriate quadrants. Typically, the lower left corner represents cell debris, while the upper right corner represents larger cell clumps. Circle the target cell population, set the gate, and proceed to the next step of analysis.
[0205] ⑤ Select the appropriate detection channel based on the fluorophore conjugated to the antibody. Adjust the corresponding channel voltage and compensation to clearly distinguish between negative and positive cell populations, and then test the experimental samples in sequence. After the test is completed, clean the flow cytometer and turn off the flow cytometer and computer.
[0206] 4. Experimental results
[0207] The four main stemness markers of HSCs are CD34, CD90, EPCR, and ITGA3. The stemness of HSCs can be assessed by the CD34 / CD90 double-positive ratio, the CD34 / EPCR double-positive ratio, and the proportion of cells positive for all four. On the day of iPSC differentiation into HSCs (denoted as Day 0), flow cytometry was performed to detect stemness markers. The results are shown in Figure 9. On Day 0, the positive proportion of CD34 in HSCs was 93.52%, the positive proportion of CD90 was 97.57%, and the proportion of CD34 and CD90 double-positive reached a high of 91.51%. The positive proportion of EPCR was approximately 17%, and the proportion of cells positive for CD34 and EPCR was 15.39%. Among the cells positive for CD34 and EPCR, the proportion positive for CD90 and ITGA3 was 10.41%. Therefore, the proportion of cells positive for all four of these three markers, CD34, CD90, EPCR, and ITGA3, was approximately 1.5%.
[0208] Two LSD1 inhibitors, OG-L002 (OG) and SP2509 (SP), were added on Day 0. High-dose, low-dose, and combination treatment groups were established. The high-dose and low-dose OG groups were 10 μM OG and 5 μM OG, respectively; the high-dose and low-dose SP groups were 2 μM SP and 1 μM SP, respectively; the combination treatment group consisted of 5 μM OG and 1 μM SP. Flow cytometry was performed every three days on Days 3, 6, and 9 to assess the stemness-maintaining effects of the two small molecules.
[0209] On Day 3, there was no significant difference in HSC cell morphology and number among the groups (see Figure 10), indicating that 3-day treatment with the LSD1 inhibitor did not affect cell proliferation.
[0210] On Day 3, the percentage of double-positive cells in the CK group dropped sharply from 91.51% to 20.82%, with a more obvious loss of stemness, and the percentage of CD34 single-positive cells was about 65%; the percentage of double-positive cells in the OG group was able to be maintained at 65%, with no significant difference between the dose groups, and the percentage of CD34 single-positive cells was able to be maintained at around 85%, with the high-dose group being lower than the low-dose group; the percentage of double-positive cells in the SP group was not significantly different from that in the CK group, and the high-dose group was 24.17%, slightly higher than the control; but the percentage of CD34 single-positive cells in the SP group was 72.9% and 74%, respectively, higher than that in the CK group; the combination drug group had the best effect, with 68.2% of double-positive cells and 87% of CD34 single-positive cells (see Figure 11).
[0211] On Day 3, the CD34 / EPCR double-positive cells in the CK group were 14.88%, and the EPCR single-positive cells were 16.5% (Day 0 were 15.39% and 16%, respectively, with basically no change); OG treatment increased the CD34 / EPCR double-positive cells to 75%, and the EPCR single-positive cells to about 80%, and OG contributed to the expression of EPCR; the EPCR in the high-dose group was slightly higher than that in the low-dose group, but CD34 was slightly lower than that in the low-dose group; the double-positive ratios in the SP group were 22.5% in the low-dose group and 25.5% in the high-dose group, both higher than the control group; the double-positive cells in the combination group increased to 80.95%; the quadruple-positive cell ratio in the CK group was 9.88%, and all the treated groups were higher than the control, among which the OG high-dose group was 21.47%, the SP low-dose group was close to 20%, and the other groups had smaller increases (see Figure 12); Overall, the results in Figure 12 show that OG has a significant promoting effect on both EPCR and CD90, and the combination group is better than the single drug group.
[0212] On Day 5, it was observed that OG treatment significantly promoted the proliferation of HSCs, while there was no significant difference between SP treatment and the control group (see FIG13 ).
[0213] On Day 6, the double-positive cells in the CK group were 17.12%, CD34 single-positive was about 47%, and CD90 single-positive was about 22.7%; the double-positive cells in the OG group decreased sharply compared with Day 3, about 28% in the 5μM group and about 26% in the 10μM group; the CD34 single-positive ratio was about 42% and 40%, lower than CK; the CD90 single-positive ratio was about 40% and 35%, higher than CK; the double-positive ratio in the SP group was slightly higher than Day 3, about 27.5% in the 1μM group and about 31% in the 2μM group; the CD34 single-positive ratio was about 63%, higher than CK; the CD90 single-positive ratio was about 33% and 39%, higher than CK; the combination drug group had the best effect, with 33.88% double-positive cells, 55% CD34 single-positive, and 40.6% CD90 single-positive (see Figure 14).
[0214] On Day 6, the percentage of CD34 / EPCR double-positive cells in the CK group was 21.54%; the percentage of double-positive cells in the OG-treated group dropped significantly, from >75% on Day 3 to about 34%; the percentage of double-positive cells in the SP group increased from about 25% on Day 3 to about 40%; the percentage of double-positive cells in the combined treatment group was 49.52%; in terms of EPCR single positivity, the percentage was about 30% in the CK group, about 47% in the OG 5μM group, and about 50.5% in the 10μM group; about 50% in the SP 1μM group, and about 54% in the 2μM group; the percentage in the combined treatment group was 68%, showing a good effect in promoting EPCR expression; the percentage of quadruple-positive cells was 13.45% in the CK group, which was not much different from that in the OG-treated group. The percentages of the SP group and the combined drug group were higher than the control, among which the percentages of the SP 1μM group, 34.13% in the 2μM group, and 23% in the combined drug group were (see Figure 15); overall, on Day 6, the SP group gradually showed a maintenance effect, and the effect of OG gradually diminished.
[0215] On Day 9, OG treatment for 9 days significantly promoted the proliferation of HSCs. In addition, 1 μM SP treatment for 9 days also promoted the proliferation of HSCs, while 2 μM SP treatment for 9 days showed no significant difference from the control group (see Figure 16).
[0216] On Day 9, the double-positive cells in the CK group dropped to 14.28%, the CD34 single-positive cells remained at only 34%, and the CD90 single-positive cells remained at only 22.5%; the OG group had lost the effect of maintaining stemness on Day 9, and the double-positive and CD34 single-positive ratios were lower than those of the control group; the double-positive ratio in the SP group was 25-30%, which was higher than that of the control group and slightly lower than that of Day 6; the effect of the combination drug group was between the OG group and the SP group (see Figure 17).
[0217] On Day 9, the trend of CD34 / EPCR was very consistent with that of CD34 / CD90. Because SP treatment for 9 days causes cell apoptosis, resulting in a two-quadrant shift in the positive signal, the actual proportion of double-positive cells should be lower than the detection value (see Figure 18). Overall, it is difficult to obtain high-stemness HSCs by Day 9 after treating HSCs with LSD1 inhibitors on Day 0. Therefore, the subsequent stemness maintenance experiment was designed to last for 1 week.
[0218] The statistical results of flow cytometry on different days are shown in Figure 19. Overall, both LSD1 inhibitors OG and SP can maintain the stemness of HSCs during in vitro culture and expansion, maintaining the high expression of the main stemness markers of HSCs (CD34 CD90 EPCR and ITGA3) for more than one week. On Day 3, the CD34 / CD90 double-positive ratio and CD34 / EPCR double-positive ratio of the 5μM and 10μM OG-treated groups were much higher than those of the other groups; on Day 6, the CD34 / CD90 double-positive ratio and CD34 / EPCR double-positive ratio of the OG-treated and SP-treated groups were much higher than those of the control group; on Day 9, the CD34 / CD90 double-positive ratio and CD34 / EPCR double-positive ratio of the SP-treated group were higher than those of the control group, while there was no significant difference between the OG-treated and control groups (see Figure 19).
[0219] Example 4 Optimization of the time window and treatment concentration conditions for maintaining stemness of iPSC-derived HSCs
[0220] 1. Cell Culture—In Vitro Expansion of HSCs and Treatment with LSD1 Inhibitors
[0221] Except for the different treatment concentrations and treatment times, other methods were the same as those described in Example 2.
[0222] Treatment concentration gradient: the gradient of OG and SP were 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, and 50 μM;
[0223] Treatment time window (i.e., the time of adding LSD1 inhibitor): Day0-1, Day0-2, Day0-3, Day0-4, Day0-5, Day0-6 (Day0-6 is reflected in the flow cytometry results of the concentration gradient, and the results of the time window show Day0-1, Day0-2, Day0-3, Day0-4, Day0-5), where Day0-1 refers to the addition of LSD1 inhibitor from day 0 for 2 consecutive days; Day0-2 refers to the addition of LSD1 inhibitor from day 0 for 3 consecutive days; Day0-3 refers to the addition of LSD1 inhibitor from day 0 for 4 consecutive days; Day0-4 refers to the addition of LSD1 inhibitor from day 0 for 5 consecutive days; Day0-5 refers to the addition of LSD1 inhibitor from day 0 for 6 consecutive days; Day0-6 refers to the addition of LSD1 inhibitor from day 0 for 7 consecutive days.
[0224] 2. Experimental results
[0225] Based on the above research results, this example further refined the treatment conditions of OG and SP, optimizing them from two perspectives: treatment concentration and treatment time window. As shown in Figure 20, on Day 3, the CD34 / CD90 double positive ratio of the CK group dropped sharply from 92.37% to 40.63%, and the EPCR / CD34 double positive ratio dropped from 53.95% to 45.42%. According to the flow cytometry results on Day 3 (see Figure 21), it can be seen that the addition of OG or OG+SP treatment can maintain the EPCR / CD34 double positive ratio above 80%. From the perspective of the treatment time window, the EPCR / CD34 double positive ratio increased with the addition of OG or OG+SP on Day 0-1, Day 0-2, and Day 0-3, indicating that the continuous addition of LSD1 inhibitors (OG or OG+SP) has a better effect.
[0226] As shown in Figure 22, OG has the best effect at concentrations between 2 and 10 μM, maintaining a double-positive ratio above 84%. As shown in Figure 23, SP has the best effect at 2 μM, maintaining a ratio of 49.34%. When the SP concentration is higher than 5 μM, it inhibits cell proliferation and may even cause cell death.
[0227] As shown in Figures 24-25, from the perspective of the treatment time window, the EPCR / CD34 double-positive ratios increased successively when OG or OG+SP was added on Day0-1, Day0-2, Day0-3, Day0-4, Day0-5, and Day0-6, indicating that the continuous addition of LSD1 inhibitors (OG or OG+SP) had a better effect.
[0228] As shown in Figures 26-27, the optimal concentration of OG is 10 μM, and the optimal concentration of SP is 2 μM. High concentrations of SP can cause cell death.
[0229] Based on the flow cytometry results on Day 3 and Day 6, the effective concentration range of OG is 2-10μM, and the effective concentration range of SP is 0.5-5μM.
[0230] Example 5 Isolation and Stemness Maintenance of Cord Blood-Derived CD34+ Cells
[0231] 1. Experimental Materials
[0232] Buffer: PBS + 0.5% BSA + 2mM EDTA solution.
[0233] 2. Sample preparation
[0234] MNC cells (human umbilical cord blood mononuclear cells) were isolated from cord blood.
[0235] (1) Filter the cells through a 30 μm cell sieve to remove cell clumps.
[0236] (2) Cell counting: determine the number of separation columns to be used based on the number of cells.
[0237] (3) Centrifuge the filtered cell suspension at 300 g for 10 minutes, discard the supernatant, and resuspend the cells in 300 μL of buffer.
[0238] (4) Every 10 8 100 μL FcR blocking reagent and 100 μL CD34 microbeads were added to the cells, mixed well, and incubated in a refrigerator (2-8°C) for 30 minutes.
[0239] (5) Every 10 8 The cells were washed by adding 5-10 mL of buffer and centrifuged at 300 g for 10 minutes.
[0240] (6) Discard the supernatant and add 10 8 Resuspend cells in 500 μL of buffer.
[0241] 3. Cell sorting
[0242] Select the appropriate column type based on the total number of CB-MNCs cells. In this experiment, LS separation column was used.
[0243] (1) Place the LS separation column in the magnetic field of the MACs separator.
[0244] (2) Rinse the separation column with 3 mL of buffer.
[0245] (3) Add the cell suspension to the separation column.
[0246] (4) Wash the separation column with an appropriate amount of buffer and collect the unlabeled cells that flow through the separation column (LS: 3×3 mL).
[0247] (5) Remove the sorting column from the sorter and place it in a suitable collection tube. Add an appropriate amount of buffer (LS: 5 mL) to the column and use the inner plug provided with the column to pressurize and flush out the bound cells.
[0248] (6) Use flow cytometry to detect the sorting purity and perform subsequent cell culture according to experimental needs.
[0249] 4. HSC Stemness Maintenance Culture
[0250] The isolated CD34+ cells were seeded into 12-well plates at a number of 20W / well for stemness maintenance. The culture medium was "HSC Stemness Maintenance and Expansion Medium" for a 9-day stemness maintenance experiment. The cell culture and LSD1 inhibitor treatment were the same as in Example 3, wherein the OG treatment concentration was 10 μM and the SP treatment concentration was 2 μM.
[0251] 5. Experimental results
[0252] CD34+ cells were isolated from cord blood using a CD34+ cell isolation kit, and flow cytometry was used to detect four HSC stemness markers: CD34, CD90, EPCR, and ITGA3. As shown in Figure 28, except for CD34, the other three markers were largely absent. Cells were seeded at 20W / well in 12-well plates to maintain stemness. 10μM OG or 2μM SP were added, with two replicates per group. Stemness markers were measured on Day 3, Day 6, and Day 9 to evaluate whether LSD1 inhibition could enhance the expression of stemness markers.
[0253] As shown in FIG29 , on Day 3 and Day 4, there were no significant differences in cell number and cell morphology among the groups.
[0254] Day 3 flow cytometry results showed that OG could significantly increase the expression of CD90 in umbilical cord blood-derived CD34-positive cells, and the proportion of CD34 and CD90 double-positive cells increased from about 0.9% in the control group to about 14%, while SP could also slightly increase the proportion of double-positive cells (see Figure 30).
[0255] The CD34 / EPCR flow cytometry results on Day 3 showed that after 3 days of culture in in vitro stemness maintenance and expansion medium, both CD34 and EPCR in the CK group had increased compared to Day 0. More importantly, OG significantly increased the expression of EPCR in cord blood-derived CD34-positive cells, with the proportion of CD34 and EPCR-positive cells increasing from approximately 6.2% in the control group to approximately 59%, an increase of nearly 10 times. SP also slightly increased the proportion of double-positive cells (see Figure 31).
[0256] As shown in Figure 32, OG and SP can increase the expression of CD90 and ITGA3 in CD34 / EPCR double-positive cells. The proportion of cells positive for the four LT-HSC markers CD34, CD90, EPCR, and ITGA3 in the control CK group was 6% x 3%, approximately 0.18%. In the OG-treated group, the proportion was 59% x 8%, approximately 4.72%, a 26-fold increase. In the SP-treated group, the proportion was 9% x 10%, approximately 0.9%, a 5-fold increase.
[0257] As shown in Figure 33, on Day 6 and Day 7, there was no significant difference in cell morphology among the groups, and the number of cells in the SP group was slightly less than that in the other two groups.
[0258] The CD34 / CD90 flow cytometry results on Day 6 showed that OG could significantly increase the expression of CD90 in umbilical cord blood-derived CD34-positive cells, and the proportion of CD34 and CD90 double-positive cells increased from about 2% in the control group to about 24%, while SP could also slightly increase the proportion of double-positive cells (see Figure 34).
[0259] On Day 6, CD34 / EPCR flow cytometry results showed that EPCR expression remained high in the OG group, with the proportion of cells positive for both CD34 and EPCR increasing from approximately 5% in the control group to approximately 40%, a nearly eight-fold increase. SP also slightly increased the proportion of cells positive for both CD34 and EPCR by approximately two-fold (see Figure 35).
[0260] As shown in Figure 36, on Day 8 and Day 9, there was no significant difference in cell morphology among the groups, and the number of cells in the SP group was slightly less than that in the other two groups.
[0261] The CD34 / CD90 flow cytometry results on Day 9 showed that CD90 was basically no longer expressed in the CK group, and the CD34 positivity rate was only about 20%. OG can significantly increase the expression of CD90 in cord blood-derived CD34-positive cells. The proportion of CD34 and CD90 double-positive cells was about 18%, and the proportion of CD34 single-positive cells was close to 50%, which was much better than the control. The proportion of double-positive cells in the SP group was about 1.5%, and the proportion of CD34 single-positive cells was about 30%, which was also better than the control group (see Figure 37). The CD34 / EPCR flow cytometry results in Figure 38 are consistent with the CD34 / CD90 flow cytometry results.
[0262] In summary, OG and SP can maintain the stemness of cord blood-derived HSCs. OG, in particular, boosts EPCR expression, achieving an EPCR / CD34 double-positive ratio of approximately 40% on Day 6 and 28% on Day 9, compared to nearly 0% in the control group. Because EPCR plays a crucial role in HSC transplantation, improving the function of cord blood-derived HSCs by inhibiting LSD1 is of great scientific significance.
[0263] The above embodiments are only provided for understanding the method and core concept of the present invention. It should be noted that, without departing from the principles of the present invention, a number of improvements and modifications may be made to the present invention by a person skilled in the art, and such improvements and modifications shall fall within the scope of protection of the claims of the present invention.
Claims
1. Application of LSD1 inhibitors in promoting the differentiation of iPSCs into HSCs.
2. The use according to claim 1, characterized in that: The LSD1 inhibitors include: OG-L002, SP2509, GSK-LSD1 2HCl, Pulrodemstat (CC-90011) besylate, Iadademstat (ORY-1001) 2HCl, Seclidemstat (SP-2577), GSK2879552 2HCl, T-3775440HCl, shRNA that reduces LSD1 expression and / or siRNA that reduces LSD1 expression.
3. The use according to claim 2, characterized in that: The LSD1 inhibitor is OG-L002 and / or SP2509.
4. The use according to claim 3, characterized in that: The OG-L002 is used at a concentration of 0.1-20 μM, and the SP2509 is used at a concentration of 0.1-5 μM.
5. The use according to claim 1, characterized in that: The HSC is a long-term hematopoietic stem cell, and the long-term hematopoietic stem cell is CD34+EPCR+CD90+ITGA3+ long-term hematopoietic stem cell.
6. Application of LSD1 inhibitors in maintaining HSC stemness.
7. The use according to claim 6, characterized in that: The LSD1 inhibitors include: OG-L002, SP2509, GSK-LSD1 2HCl, Pulrodemstat (CC-90011) besylate, Iadademstat (ORY-1001) 2HCl, Seclidemstat (SP-2577), GSK2879552 2HCl, T-3775440HCl, shRNA that reduces LSD1 expression and / or siRNA that reduces LSD1 expression.
8. The use according to claim 7, characterized in that: The LSD1 inhibitor is OG-L002 and / or SP2509.
9. The use according to claim 8, characterized in that: The OG-L002 is used at a concentration of 2-10 μM, and the SP2509 is used at a concentration of 0.5-5 μM.
10. The use according to claim 6, characterized in that: The HSCs include iPSC-derived HSCs or umbilical cord blood-derived HSCs.
11. The use according to claim 6, characterized in that: The LSD1 inhibitor can maintain the expression of HSC stemness-related genes CD34, CD90, EPCR, and ITGA3, and increase the expression level of EPCR.
12. A method for promoting differentiation of iPSC into HSC, characterized in that: The LSD1 inhibitor according to any one of claims 1 to 4 is used to promote the differentiation of iPSC into HSC.
13. The method according to claim 12, characterized in that The method comprises the following steps: (1) Day-1, iPSC monolayer adherent cell formation; (2) Day 0, mesendoderm induction, culturing the iPSCs obtained in step (1) using mesendoderm induction medium; (3) Day 1-2, hematopoietic mesoderm specialization, culturing the cells obtained in step (2) using hematopoietic mesoderm specialization medium; (4) Day 3-Day 12, hemogenic endothelial specialization and endothelial-hematopoietic cell transformation. The cells obtained in step (3) are cultured in a hemogenic endothelial specialization and endothelial-hematopoietic cell transformation medium, and a LSD1 inhibitor is added. On Day 12, HSC cells are collected.
14. The method according to claim 13, characterized in that The mesoderm induction medium in step (2) comprises: STEMdiff TM APEL TM 2Medium, 1% Penicillin-Streptomycin, 9μM CHIR99021.
15. The method according to claim 13, characterized in that The hematopoietic mesoderm-specific culture medium in step (3) comprises: STEMdiff TM APEL TM 2Medium, 1% Penicillin-Streptomycin, 20ng / mL VEGF, 20ng / mL bFGF.
16. The method according to claim 13, characterized in that The hemogenic endothelial specialization and endothelial-hematopoietic cell conversion culture medium in step (4) comprises: STEMdiff TM APEL TM 2Medium, 1% Penicillin-Streptomycin, 20ng / mL VEGF, 20ng / mL bFGF, 20ng / mL SCF, 10ng / mL IL-3, 30ng / mL TPO, 10ng / mL Flt-3L, 10ng / mL BMP4.
17. The method according to claim 16, characterized in that The hemogenic endothelial specialization and endothelial-hematopoietic cell conversion medium further contains Y-27632.
18. The method according to claim 17, characterized in that The concentration of Y-27632 was 10 μM.
19. The method according to claim 13, characterized in that The LSD1 inhibitor in step (4) is added on Day 6 or Day 9.
20. The method according to claim 13, characterized in that The LSD1 inhibitor in step (4) is the LSD1 inhibitor described in any one of claims 1-4.
21. The method according to claim 13, characterized in that The HSC is a long-term hematopoietic stem cell, and the long-term hematopoietic stem cell is CD34+EPCR+CD90+ITGA3+ long-term hematopoietic stem cell.
22. A method for maintaining HSC stemness, characterized in that: The method comprises the following steps: culturing HSC in an HSC stemness maintenance and expansion medium, and adding a LSD1 inhibitor.
23. The method according to claim 22, characterized in that The HSC stemness maintenance and expansion culture medium comprises: StemSpan TM SFEM Medium, 50ng / mL Flt3L, 50ng / mL SCF, 50ng / mL TPO, 10ng / mL IL-3, 35nM UM171, 1μM VPA, 50μg / mL LAA, 50μM Trolox, 50μMNAC, 0.5μM SR1, 1% PVA, 1% ITS-X.
24. The method according to claim 22, characterized in that The LSD1 inhibitor is the LSD1 inhibitor described in any one of claims 6-9.
25. The method according to claim 22, characterized in that The HSCs include iPSC-derived HSCs or umbilical cord blood-derived HSCs.
26. The method according to claim 22, characterized in that The LSD1 inhibitor can maintain the expression of HSC stemness-related genes CD34, CD90, EPCR, and ITGA3, and increase the expression level of EPCR.
Citation Information
Patent Citations
Metabolic guided permanent lineage specifying during endothelial cell to hematopoietic cell transition
CN114981412A
Method for preparing hematopoietic endothelial cells and method for preparing hematopoietic stem cells or hematopoietic stem progenitor cells
CN115247151A
Application of LSD1 inhibitor in promoting differentiation of iPSC to HSC and stemness maintenance of HSC
CN116445408A
Methods and compositions for expansion of stem cells and other cells
US20150250824A1
Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
US20180187156A1
